Johnson Chemical Pharmaceutical Works Co., Ltd.

As of June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. carries a market capitalization of 2.22B, placing it among publicly traded companies globally. Its enterprise value stands at 2.60B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. has 90.92M shares outstanding.

As of June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. trades at a trailing price-to-earnings ratio of 24.63. The price-to-sales ratio is 3.81, and the price-to-book ratio stands at 1.27.

As of June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. trades at an EV/EBITDA multiple of 32.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 44.10 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 2.60B versus a market cap of 2.22B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. maintains a current ratio of 0.73, meaning it holds 0.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 37.10, indicating elevated leverage, while an interest coverage ratio of 6.98 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. posted a return on equity (ROE) of 5.25, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 2.67 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.92, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 4.77, useful for judging operating efficiency across full business cycles. The company generates approximately 3.22M in revenue per employee across its workforce of 179.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.94 indicates how many times Johnson Chemical Pharmaceutical Works Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. recorded 4.33M in income tax expense. That works out to an effective tax rate of 4.62, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 93.70M, leaving 89.38M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd.'s stock has declined approximately 33.04% over the past 52 weeks. The 50-day moving average sits at 24.65, while the 200-day moving average is 26.86.

Over the twelve months ended June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. generated 577.93M in revenue and converted that into 89.38M in net income, yielding earnings per share of 0.98. EBITDA reached 79.33M, while operating income came in at 59.17M.

As of June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. holds 261.73M in cash and equivalents against 645.00M in total debt, resulting in a net debt position of 383.27M. Total book value stands at 1.74B, with working capital of -217.38M providing operational flexibility.

Johnson Chemical Pharmaceutical Works Co., Ltd. produced 24.29M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -65.16M in capital expenditures, free cash flow totaled -40.87M - equivalent to -0.45 per share.

Over the twelve months ended June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. posted a gross margin of 39.30, reflecting its pricing power and cost economics. The operating margin of 10.24 and net profit margin of 15.47 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield is negative at -1.83: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -20.07, meaning Johnson Chemical Pharmaceutical Works Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Johnson Chemical Pharmaceutical Works Co., Ltd.'s most recent stock split took place on August 20, 2026 with a 1:2 split ratio.

As of June 30, 2026, Johnson Chemical Pharmaceutical Works Co., Ltd. has an Altman Z-Score of 1.86, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.